Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rapamycin in Relapsed Acute Lymphoblastic Leukemia.

Trial Profile

Rapamycin in Relapsed Acute Lymphoblastic Leukemia.

Phase of Trial: Phase II

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs Sirolimus (Primary) ; Corticosteroids; Corticosteroids
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 12 Feb 2016 Planned End Date changed from 1 Oct 2015 to 1 Apr 2016, according to ClinicalTrials.gov record.
    • 24 Apr 2013 Planned end date changed from 1 Oct 2012 to 1 Oct 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top